Liang DENG,Stewart SHUMAN,Jedd WOLCHOK,Taha MERGHOUB,Weiyi WANG,Peihong DAI,Ning Yang
申请号：
US16845809
公开号：
US20200316198A1
申请日:
2020.04.10
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fins-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.
